Notch signaling in cancer stem cells

Advances in Experimental Medicine and Biology

Volumn 727, Issue , 2012, Pages 174-185

  Wang, Jialiang ^a,b   Sullenger, Bruce A ^a   Rich, Jeremy N ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LAPATINIB; NOTCH RECEPTOR; OXALIPLATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL PROTECTION; CELL RENEWAL; CELL SURVIVAL; COLON CANCER; GLIOMA; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; LIVER CANCER; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION PROTECTION; SIGNAL TRANSDUCTION; ANIMAL; CYTOLOGY; METABOLISM; PATHOLOGY; REVIEW; STEM CELL;

ERINACEIDAE;

ANIMALS; HUMANS; NEOPLASTIC STEM CELLS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84859496112     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0899-4_13     Document Type: Article

References (108)

1. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol Ther 2009; 17:219-230.
2. Eyler CE, Rich TN. Survival of the fittest: Cancer stem cells in therapeutic resistance arni aigiogenesis. J Clin Oncol 2008; 26:2839-2845.
3. Huang EH, Heidt DO, Li CW et al. Cancer stem cells: A new paradigm for understanding tumor progression and therapeutic resistance. Surgery 2007; 14 1:415-419.
4. Pajonlc F, Vlashi E, McBride WH. Radiation resistance ofcancer stem cells: The 4 R's ofradiobiology revisited. Stem Cells 2010; 28:639-648.
5. Stylianou S, Clarke RB, Brennan K. Abenant activation of notch signaling in human breast cancer. Cancer Res 2006; 66:15 17-1525.
6. Demarest RM, Ratti F, Capobianco AT. It's T-ALL about Notch. Oncogene 2008; 27:5082-5091.
7. van Es JH, van Oijn ME, Riccio O et al. Notch gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435:959-963.
8. Weng AP, Fenando AA, Lee Wet al. Activating mutations ofNOTCH1 in human T-cell acute lymphoblastic leukemia. Science 2004; 306:269-271.
9. Farnie O, Clarke RB. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 2007; 3:169-17 5.
10. Pierfelice TJ, Schreck KC, Eberhart CO et al. Notch, neural stem cells and brain tumors. Cold Spring Harb Symp Quant Biol 2008; 73:367-375.
11. Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol 2009; 27:44-46.
12. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia afler transplantation into SCID mice. Nature 1994; 367:645-648.
13. Al-Hajj M, Wicha MS, Benito-Hemandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988.
14. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-5828.
15. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401.
16. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110.
17. Ricci-Vitiani L, Lombardi DO, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-115.
18. Li C, HeidtDO, DalerbaP et al. Identificationofpancreatic cancer stem cells. CancerRes 2007; 67:1030-1037.
19. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-10951.
20. Eramo A, Lotti F, Sette Octal. Identification and expansion ofthe tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15:504-514.
21. Yang ZF, Ho DW, Ng MN et al. Significance of CD90 cancer stem cells in human liver cancer. Cancer Cell 2008; 13:153-166.
22. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104:973-978.
23. Moserle L, Ghisi M, Amadori A.et al. Side population and cancer stem cells: Therapeutic implications. Cancer Lett. 288:1-9.
24. Schatton T, Murphy OF, Frank NY et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-349.
25. Armstrong L, Stojkovic M, Dimmick I et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22:1142-1151.
26. Hess DA, Meyenose TE, Wirthlin Let al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104:1648-1655.
27. Oinestier C. Hur MH. Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-567.
28. Liu R, Wang X, Chen OY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engi J Med 2007; 356:217-226.
29. Abraham BK, Fritz P, McClellan Metal. Prevalence of CD44 CD24 low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11:1154-1159.
30. van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11:6520-6527.
31. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD 133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14:123-129.
32. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-284.
33. Diehn M, Cho RW, Clarke MF. Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol 2009; 19:78-8 6.
34. Li X, Lewis MT, Huang Jet al. Intrinsic resistance oftumorigenic breast cancer cells to chemotherapy. J Natl Cancer In,t 2008; 100:672-679.
35. Eramo A, Ricci-Vitiani L, Zeuner A et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13:1238-1241.
36. Hermann PC, Huber SL, Henler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-323.
37. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389-402.
38. Levina V, Marrangoni AM, DeMarco Ret al. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008; 3:e3077.
39. OuanY, Oerhard B, Hogge DE. Detection, isolation and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-3149.
40. Holyoake T, Jiang X, Eaves C et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94:2056-2064.
41. Zheng H, Ying H, Yan H et al. p53 and Pten control neural and glioma stemlprogenitor cell renewal and differentiation. Nature 2008; 455:1129-1133.
42. Wang J, Wang H, Li Z et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 2008; 3:e3769.
43. Liu O, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance ofCD133 cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67.
44. Bao S, Wu Q, McLendon RE et al. Olioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760.
45. Blazek ER, Foutch IL, Maki O. Daoy medulloblastoma cells that express CD 133 are radioresistant relative to CD 133-cells and the CD1 33 sector is enlarged by hypoxia. Tnt J Radiat Oncol Biol Phys 2007; 67:1-5.
46. Phillips TM, McBride WH, Pajonic F. The response of CD24( low) CD44 breast cancer-initiating cells to radiation. J Nati Cancer Inst 2006; 98:1777-1785.
47. Diehn M, Cho RW, Lobo NA et al. Association ofreactive oxygen species levels and radioresistance in cancer stern cells. Nature 2009; 45 8:780-783.
48. Leach JK, Van Tuyle O, Lin PS et al. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygenlnitrogen. Cancer Res 2001; 61:3894-3901.
49. WoodwardWA, ChenMS, BehbodF et al. WNT/beta- cateninmediatesradiationresistance ofmousemammary progenitor cells. Proc Natl Acad Sci USA 2007; 104:618-623.
50. Muller JM, Chewier L, Cochaud S et al. Notch and Wnt developmental pathways as targets for anti-cancer drugs. Drug Discovery Today: Disease Mechanisrns 2007; 4:285-291.
51. Wang Z, Li Y, Banerjee Set al. Emerging role of Notch in stem cells and cancer. Cancer Left 2009; 279:8-12.
52. Bolos V, Grego-Bessa J, de la Pornpa JL. Notch signaling in developrnent and cancer. Endocr Rev 2007; 28 :339-3 63.
53. Pece S, Senesi M, Santolini E et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004; 167:215-221.
54. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol 2004; 14:341-347.
55. Kanamori M, Kawaguchi T, Nigro JM et al. Contribution of Notch signaling activation to human glioblastoma multiforme. JNeurosurg 2007; 106:417-427.
56. Purow BW, Haque RM, Noel MW et al. Expression of Notch-i and its ligands, Delta-like-i and Jagged-i, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65:2353-2363.
57. Nicolas M, Wolfer A, Raj K et al. Notchi functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33 :4 16-421.
58. Proweller A, Tu L, Lepore JJ et al. Irnpaired notch signaling prornotes de novo squarnous cell carcinorna formation. Cancer Res 2006; 66:7438-7444.
59. OkuyamaR.NguyenBC. TaloraC et al. High conmitmentofembryonickeratinocytestoterminaldifferentiation through a Notch1-caspase 3 regulatory rnechanisrn. Dcv Cell 2004; 6:551-562.
60. Rangarajan A, Talora C, Okuyama R et al. Notch signaling is a direct determinant of keratinocyte growth anest and entry into differentiation. EMBO J 2001; 20:3427-3436.
61. Yoon K Gaiano N. Notch signaling in the mammalian central nervous syste(1): Insights from mouse mutants. Nat Neurosci 2005; 8:709-715.
62. Androutsellis-Theotokis A, Leker RR, Soldner F et al. Notch signalling regulates stem cell numbers in vitro and in xho. Nature 2006; 442:823-826.
63. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engrafiment in embryonal brain tumors. Cancer Res 2006; 66:7445-7452.
64. Fan X, Khaki L, Zhu TS et al. NOTCH pathway blockade depletes CD 133 positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografls. Stem Cells 2010; 28:5-16.
65. Liu S, Dontu O, Wicha MS. Mammary stem cells, self-renewal pathways and carcinogenesis. Breast Cancer Res 2005; 7:86-95.
66. Dontu O, Jackson KW, McNicholas E et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004; 6:R605-R615.
67. Bouras T, Pal B, Vaillant F et al. Notch signaling regulates mammary stem cell function and luminal cell-fate cornrnitrnent. Cell Stern Cell 2005; 3:429-441.
68. Buono KD, Robinson 0W, Martin C et al. The canonical NotchIRBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dcv Biol 2006; 293:565-580.
69. Dickson BC, Mulligan AM, Zhang H et al. High-level JAUI rnRNA and protein predict poor outcorne in breast cancer. Mod Pathol 2007; 20:685-693.
70. Reedijk M, Odorcic S, Chang Let al. High-level coexpression ofJAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65:8530-8537.
71. Magnifico A, Albano L, Campaner S et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highestoncoproteinlevels andare sensitiveto trastuzumab. ClinCancerRes 2009; 15:2010-2021.
72. Phillips TM, Kim K, Vlashi E et al. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007; 9:1122-1129.
73. Sansone P, Storci O, Giovannini C et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stemlprogenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007; 25:807-815.
74. Sansone P, Storci O, Tavolari S et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117:3988-4002.
75. Gal H, Amariglio N, Trakhtenbrot L et al. Gene expression profiles of AML derived stem cells; similarity to hernatopoietic stern cells. Leukernia 2006; 20:2147-2154.
76. DeAngelis LM, Brain turnors. N Engl I Med 2001; 344:114-123.
77. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31:635-644.
78. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy pius concomitant and adjuvant temozolomide for glioblastoma. N Engi J Med 2005; 352:987-996.
79. Scharpfenecker M, Kruse JJ, Sprong D et al. Ionizing radiation shifis the PM-i ID-i balance and activates notch signaling in endothelial cells. Tnt J Radiat Oncol Biol Phys 2009; 73:506-5 13.
80. Wang J, Wakeman TP, Lathia JD et al. Notch Promotes Radioresistance of Glioma Stem Cells. Stem Cells 2010; 28:17-28.
81. SadeH, Krishna S, SarinA. The anti-apoptotic effect ofNotch-1 requires pS6lck-dependent,Akt/PKB-mediated signaling in I-cells. J Biol Chem 2004; 279:2937-2944.
82. Perumalsamy LR, Nagala M, Banerjee P et al. A hierarchical cascade activated by noncanonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced death in mammalian cells. Cell Death Differ 2009; 16:879-889.
83. Palomero T, Sulis ML, Cortina M et al. Mutational loss of PTEN induces resistance to NOTCH 1 inhibition in T-cell leukemia. Nat Med 2007; 13:1203-1210.
84. Gutierrez A, Look AT. NOTCH and PT3K-AKT pathways intertwined. Cancer Cell 2007; 12:411-413.
85. Calzavara E, Chiaramonte R, Cesana D et al. Reciprocal regulation of Notch and PI3KIAkt signalling in T-ALL cells in vitro. J Cell Biochem 2008; 103:1405-1412.
86. Mungamuri SK, Yang X, Thor AD et al. Survival signaling by Notch 1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66:47 15-4724.
87. Eyler CE, FooWC, LaFiura KM et al. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008; 26:3027-3036.
88. Phillips HS, Kharbanda S, ChenRetal. Molecular subclasses othigh-grade gliomapredict prognosis, delineate a pattern of disease progression and resemble stages in neurogenesis. Cancer Cell 2006; 9:157-173.
89. Pannuti A, Foreman K, Rizzo P et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010; 16 :3 141-3 152.
90. Takebe N Ivy. SP. Controversies in cancer stem cells: Targeting embryonic signaling pathways. Clin Cancer Res 2010; 16:3106-3112.
91. Shih Ic M, Wang TL. Notch signaling, gamma-secretase inhibitors and cancer therapy. Cancer Res 2007; 67:1879-1882.
92. Armogida M, Petit A, Vincent B et al. Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol 2001; 3:1030-1033.
93. Huppert SS, Le A, Schroeter EH et al. Embryonic lethality in mice homozygous for a processing-deficient allele ofNotchi. Nature 2000; 405:966-970.
94. Imbimbo BP. Alzheimer's disease: [gamma]-secretase inhibitors. Drug Discovery Today: Therapeutic Strategies 2008; 5:169-175.
95. O'Neil J, Calvo J, McKenna K et al. Activating Notch 1 mutations in mouse models of T-ALL. Blood 2006; 107:781-785.
96. Curry CL, Reed LL, Golde TE et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005; 24:6333-6344.
97. Hallahan AR, Pritchard JT, Ham,en S et al. The SmoAl mou,e model rewah that notch ignaling i critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004; 64:7794-7800.
98. Wang L, Rahn JJ, Lun X et al. Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol 2008; 6:e289.
99. Loane DJ, Pocivavsek A, Moussa CE et al. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat Med 2009; 15:377-379.
100. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Cun Top Med Chem 2008; 8:54-61.
101. Dovey HF, John V, Anderson JP et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76:173-181.
102. Arumugam TV, Chan SL, Jo DG et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 2006; 12:621-623.
103. Osipo C, Golde TE, Osborne BA et al. Off the beaten pathway: The complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88:11-17.
104. Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27:5115-5123.
105. Fan X, Mikolaenlco I, Elhassan I et al. Notch 1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64:7787-7793.
106. Graziani I, Eliasz S, Dc Marco MA et al. Opposite effects of Notch-i and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res 2008; 68 :9678-9685.
107. Aste-Amézaga M, Zhang N, Lineberger JE et al. Characterization ofNotchi antibodies that inhibit signaling of both normal and mutated Notchi receptors. PLoS ONE5:e9094.
108. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5:168-177.